Protalix BioTherapeutics Q3 Earnings Preview
Source: SeekingAlpha
2025-11-12 11:03:56 ET
More on Protalix BioTherapeutics
- Protalix: Speculative Buy On Promising Plant-Cell Platform And Elfabrio Ramp
- Protalix BioTherapeutics, Inc. (PLX) Q2 2025 Earnings Call Transcript
- Protalix signals $100M+ Elfabrio royalties by 2030 as Phase II PRX-115 trial advances
- Seeking Alpha’s Quant Rating on Protalix BioTherapeutics
- Historical earnings data for Protalix BioTherapeutics
Read the full article on Seeking Alpha
For further details see:
Protalix BioTherapeutics Q3 Earnings Preview
Protalix BioTherapeutics Inc.
NASDAQ: PLX
PLX Trading
4.59% G/L:
$2.965 Last:
287,012 Volume:
$2.88 Open:
PLX Latest News
March 09, 2026 06:00:00 am
Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa)
January 30, 2026 09:47:43 am
Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) in the EU
December 17, 2025 06:50:00 am
Protalix Biotherapeutics and Secarna Pharmaceuticals Enter into Collaboration and Option Agreement
PLX Stock Data
$215,126,659
70,448,955
0.23%
25
N/A
Biotechnology & Life Sciences
Healthcare
US
Hackensack
